---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-015445"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-04-07T23:59:59+00:00"
generated_at: "2026-05-15T07:03:27.689635+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Technologies' CyPath Lung featured at Cleveland Clinic symposium Apr 16

## Summary
- CyPath Lung test to be highlighted at invitation-only 'Advances in Early Lung Cancer Detection' symposium.
- CMO Gordon Downie, MD, PhD, to serve on panel discussing lung nodule management.
- Test has demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting early-stage lung cancer.
- This marks the company's seventh invitation to present at the Cleveland Clinic symposium.

## SEC filing metadata
- accession: 0001493152-26-015445
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-04-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226015445/0001493152-26-015445-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226015445/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-015445
- JSON: https://secwatch.observer/filing/0001493152-26-015445.json
- Plain text: https://secwatch.observer/filing/0001493152-26-015445.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.